KR20140018966A - 점도가 감소된 제제 - Google Patents

점도가 감소된 제제 Download PDF

Info

Publication number
KR20140018966A
KR20140018966A KR1020137029163A KR20137029163A KR20140018966A KR 20140018966 A KR20140018966 A KR 20140018966A KR 1020137029163 A KR1020137029163 A KR 1020137029163A KR 20137029163 A KR20137029163 A KR 20137029163A KR 20140018966 A KR20140018966 A KR 20140018966A
Authority
KR
South Korea
Prior art keywords
formulation
viscosity
less
concentration
citrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137029163A
Other languages
English (en)
Korean (ko)
Inventor
미르나 에이. 몬크
맨 이 왕
카이 장
Original Assignee
글락소스미스클라인 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 엘엘씨 filed Critical 글락소스미스클라인 엘엘씨
Publication of KR20140018966A publication Critical patent/KR20140018966A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020137029163A 2011-04-07 2012-04-06 점도가 감소된 제제 Withdrawn KR20140018966A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161473121P 2011-04-07 2011-04-07
US61/473,121 2011-04-07
PCT/US2012/032462 WO2012138958A1 (en) 2011-04-07 2012-04-06 Formulations with reduced viscosity

Publications (1)

Publication Number Publication Date
KR20140018966A true KR20140018966A (ko) 2014-02-13

Family

ID=46969561

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137029163A Withdrawn KR20140018966A (ko) 2011-04-07 2012-04-06 점도가 감소된 제제

Country Status (12)

Country Link
US (1) US20140023655A1 (cg-RX-API-DMAC7.html)
EP (2) EP2694100A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014516924A (cg-RX-API-DMAC7.html)
KR (1) KR20140018966A (cg-RX-API-DMAC7.html)
CN (1) CN103596585A (cg-RX-API-DMAC7.html)
AU (2) AU2012240050B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013025866A2 (cg-RX-API-DMAC7.html)
CA (1) CA2832556A1 (cg-RX-API-DMAC7.html)
EA (1) EA201391488A1 (cg-RX-API-DMAC7.html)
IL (1) IL228591A0 (cg-RX-API-DMAC7.html)
SG (1) SG193963A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012138958A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3295957T (pt) * 2010-01-15 2019-11-12 Kirin Amgen Inc Formulação de anticorpo anti il-17ra e regimes terapêuticos para o tratamento de psoríase
BR112014010186A2 (pt) * 2011-10-28 2017-05-02 Integritybio Inc formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
WO2014141149A1 (en) * 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
WO2014169153A1 (en) * 2013-04-10 2014-10-16 Echogen, Inc. Peptide complexes and therapeutic uses
JP6179939B2 (ja) * 2013-07-09 2017-08-16 国立大学法人 筑波大学 高濃度γグロブリン製剤の粘度低下方法
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EP3200804A4 (en) 2014-10-01 2018-04-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
EP3804747A1 (en) * 2015-01-18 2021-04-14 Gloriana Therapeutics, Inc. Therapeutic protein formulations
PH12018500379B1 (en) 2015-08-24 2022-11-23 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CN113507938B (zh) 2019-03-29 2024-04-16 广东恒瑞医药有限公司 包含抗il-5抗体的药物组合物及其用途
JP2023533704A (ja) * 2020-07-13 2023-08-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 高濃度タンパク質製剤用の粘度低減賦形剤及びそれらの組み合わせ

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5747447A (en) * 1992-04-30 1998-05-05 Cor Therapeutics Stable polypeptide composition
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
EP1324776B2 (en) * 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU2002319544B2 (en) 2001-08-10 2008-07-10 Aberdeen University Antigen binding domains from fish
ATE352316T1 (de) * 2002-11-01 2007-02-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzung
US20050053666A1 (en) * 2002-12-31 2005-03-10 Stelios Tzannis Antibody-containing particles and compositions
JP4869064B2 (ja) * 2003-04-04 2012-02-01 ジェネンテック, インコーポレイテッド 高濃度抗体及びタンパク質製剤
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
EP1962907A2 (en) * 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
US9084777B2 (en) * 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
EP2129401B8 (en) * 2006-12-21 2020-01-15 Amgen Inc. Stable buffered formulations containing polypeptides
ES2750254T3 (es) * 2007-09-27 2020-03-25 Amgen Inc Formulaciones farmacéuticas
AR069495A1 (es) * 2007-11-30 2010-01-27 Glaxo Group Ltd Construcciones de union de antigenos para el tratamiento de cancer o enfermedades inflamatorias (asma, artritis o artrosis)
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
PT3295957T (pt) * 2010-01-15 2019-11-12 Kirin Amgen Inc Formulação de anticorpo anti il-17ra e regimes terapêuticos para o tratamento de psoríase
WO2011095543A1 (en) * 2010-02-04 2011-08-11 Csl Behring Ag Immunoglobulin preparation
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
SG193964A1 (en) * 2011-04-07 2013-11-29 Glaxosmithkline Llc Formulations with reduced viscosity

Also Published As

Publication number Publication date
BR112013025866A2 (pt) 2016-12-20
SG193963A1 (en) 2013-11-29
EP2694100A1 (en) 2014-02-12
IL228591A0 (en) 2013-12-31
AU2012240050A1 (en) 2013-10-17
EP3058952A1 (en) 2016-08-24
AU2012240050B2 (en) 2016-01-21
CA2832556A1 (en) 2012-10-11
JP2014516924A (ja) 2014-07-17
CN103596585A (zh) 2014-02-19
EP2694100A4 (en) 2014-10-01
WO2012138958A1 (en) 2012-10-11
EA201391488A1 (ru) 2014-01-30
US20140023655A1 (en) 2014-01-23
AU2016202355A1 (en) 2016-05-05

Similar Documents

Publication Publication Date Title
KR20140066124A (ko) 점도가 감소된 제제
KR20140018966A (ko) 점도가 감소된 제제
JP6541581B2 (ja) 低濃度抗体製剤
ES2791690T3 (es) Formulaciones liofilizadas
CN106659785B (zh) 包含gm-csf中和化合物的液体制剂
KR102106914B1 (ko) Gm-csf를 중화하는 화합물을 포함하는 액체 제제
JP2022500386A (ja) Csf−1r抗体製剤
KR20230009897A (ko) 항-IL-23p19 항체를 포함하는 제제, 이의 제조방법 및 용도
JPWO2008029908A1 (ja) 抗体を含有する安定な凍結乾燥医薬製剤
WO2014141149A1 (en) Formulations with reduced viscosity
JP7502286B2 (ja) 抗pcsk9抗体を含む安定製剤
CN119095618B (zh) 用于治疗巨噬细胞活化综合征的组合物和方法
CN119095618A (zh) 用于治疗巨噬细胞活化综合征的组合物和方法
JP2024539265A (ja) 製剤
EA040788B1 (ru) Жидкая композиция, содержащая соединение, нейтрализующее gm-csf

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131104

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid